Arbutus Biopharma Corp (ABUS) stock
ABUSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 14/3073% below fair value
$4.05+0.01 (+0.25%)
Close on Nov 17, 2026Market cap $801.28MP/E 5.2Yield –
Arbutus Biopharma net income
Net income is the profit left for shareholders after every expense, interest and tax.
Arbutus Biopharma's net income for the twelve months ending Jun 30, 2026 was $153.05M. For fiscal 2025 it was -$33.50M. The highest annual figure on record is $29.61M in fiscal 2012.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$33.50M | – |
| FY2024 | Dec 31, 2024 | -$69.92M | – |
| FY2023 | Dec 31, 2023 | -$72.85M | – |
| FY2022 | Dec 31, 2022 | -$69.46M | – |
| FY2021 | Dec 31, 2021 | -$76.25M | – |
| FY2020 | Dec 31, 2020 | -$63.75M | – |
| FY2019 | Dec 31, 2019 | -$153.72M | – |
| FY2018 | Dec 31, 2018 | -$57.06M | – |
| FY2017 | Dec 31, 2017 | -$84.41M | – |
| FY2016 | Dec 31, 2016 | -$384.16M | – |
| FY2015 | Dec 31, 2015 | -$62.72M | – |
| FY2014 | Dec 31, 2014 | -$38.84M | – |
| FY2013 | Dec 31, 2013 | -$14.06M | -147.5% |
| FY2012 | Dec 31, 2012 | $29.61M | – |
| FY2011 | Dec 31, 2011 | -$10.08M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.14M | -303.8% |
| Q1 FY2026 | Mar 31, 2026 | $169.70M | – |
| Q4 FY2025 | Dec 31, 2025 | -$3.76M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.74M | – |
| Q2 FY2025 | Jun 30, 2025 | $2.52M | – |
| Q1 FY2025 | Mar 31, 2025 | -$24.53M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.53M | – |
| Q3 FY2024 | Sep 30, 2024 | -$19.72M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.80M | – |
| Q1 FY2024 | Mar 31, 2024 | -$17.88M | – |
| Q4 FY2023 | Dec 31, 2023 | -$19.31M | – |
| Q3 FY2023 | Sep 30, 2023 | -$20.10M | – |
| Q2 FY2023 | Jun 30, 2023 | -$17.09M | – |
| Q1 FY2023 | Mar 31, 2023 | -$16.34M | – |
| Q4 FY2022 | Dec 31, 2022 | -$21.93M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.57M | – |
| Q2 FY2022 | Jun 30, 2022 | -$14.19M | – |
| Q1 FY2022 | Mar 31, 2022 | -$15.77M | – |
| Q4 FY2021 | Dec 31, 2021 | -$21.32M | – |
| Q3 FY2021 | Sep 30, 2021 | -$19.16M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.39M | – |
| Q1 FY2021 | Mar 31, 2021 | -$16.38M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.04M | – |
| Q3 FY2020 | Sep 30, 2020 | -$18.76M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.09M | – |
| Q1 FY2020 | Mar 31, 2020 | -$13.86M | – |
| Q4 FY2019 | Dec 31, 2019 | -$24.65M | – |
| Q3 FY2019 | Sep 30, 2019 | -$82.50M | – |
| Q2 FY2019 | Jun 30, 2019 | -$23.32M | -854.3% |
| Q1 FY2019 | Mar 31, 2019 | -$23.25M | – |
| Q4 FY2018 | Dec 31, 2018 | -$18.25M | – |
| Q3 FY2018 | Sep 30, 2018 | -$24.47M | – |
| Q2 FY2018 | Jun 30, 2018 | $3.09M | – |
| Q1 FY2018 | Mar 31, 2018 | -$17.43M | – |
| Q4 FY2017 | Dec 31, 2017 | -$35.93M | – |
| Q3 FY2017 | Sep 30, 2017 | -$11.60M | – |
| Q2 FY2017 | Jun 30, 2017 | -$18.26M | – |
| Q1 FY2017 | Mar 31, 2017 | -$18.63M | – |
| Q4 FY2016 | Dec 31, 2016 | -$218.70M | – |
| Q3 FY2016 | Sep 30, 2016 | -$19.60M | – |
See a number that looks wrong?